| Literature DB >> 30709408 |
Fitriana Murriya Ekawati1,2, Sharon Licqurish3, Ova Emilia4, Jane Gunn5, Shaun Brennecke6,7, Phyllis Lau5.
Abstract
BACKGROUND: National and international guidelines for the management of hypertensive disorders of pregnancy (HDP) are available in developing countries. However, more detailed clinical pathways for primary care settings are limited. This study focuses on Indonesia, where 72% of women who died from HDP and its complications had received less appropriate treatment according to international guidelines. There is an urgent need to develop primary care focused pathways that enable general practitioners (GPs), midwives and other relevant providers to manage HDP better.Entities:
Keywords: Acceptability; Delphi technique; Feasibility; Hypertension; Implementation science; Pilot study; Pregnancy; Primary care
Mesh:
Year: 2019 PMID: 30709408 PMCID: PMC6359831 DOI: 10.1186/s12978-019-0674-0
Source DB: PubMed Journal: Reprod Health ISSN: 1742-4755 Impact factor: 3.223
Fig. 1Theoretical framework adapted from an amalgamation of the MRC and PRISM frameworks
Fig. 2Design of the study phases
Guiding questions for interviews in exploratory phase
| Project theoretical frameworks | Group of participants involved in the exploratory phase | Guiding questions for the participants |
|---|---|---|
| Intervention | Primary care providers | How is HDP usually managed in primary care? |
| Recipients’ (individuals involved in intervention implementation) characteristic | Obstetricians | What do you think about HDP management in primary care? |
| Policy makers & key informants | ||
| What are the current guidelines to manage hypertension in pregnancy in primary care? | ||
| Women | ||
| What are things work well? | ||
| What are things need to be improved? | ||
| What is your experience of having HDP treatment in primary care? | ||
| External Environment | ||
| What are things work well? | ||
| What are things need to be improved? | ||
|
|
Lists of reviewed international and Indonesian HDP guidelines
| International Guidelines | Country of origin | Indonesian Guidelines |
|---|---|---|
| National Institute for Health Care Excellence (NICE) guidelines [ | United Kingdom | WHO-SEARO Indonesian guidelines for pregnancy complications [ |
| Preeclampsia Community Guideline (PRECOG) I [ | United Kingdom | |
| PRECOG II [ | United Kingdom | Yogyakarta referral manuals for pregnancy complication [ |
| The European Society of Cardiologists (ESC) [ | European consensus | Indonesian Obstetrics and Gynaecology Association (POGI) guideline for preeclampsia [ |
| Netherland’s multidisciplinary guideline for cardiovascular diseases in pregnancy [ | Netherland | |
| American Congress of Obstetricians and Gynecologists (ACOG) [ | United States | |
| The American Society of Hypertension (ASH) [ | United States | |
| The Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) guideline [ | Australia | |
| Queensland State Guideline for HDP [ | Australia | |
| The Society of Obstetricians and Gynaecologists of Canada (SOGC) [ | Canada | |
| The Association of Ontario Midwives (AOM) guideline on hypertensive disorders of pregnancy [ | Canada | |
| The ISSHP recommendation (2018) [ | International consensus | |
| France’s consensus statement for hypertensive disorder in pregnancy [ | France | |
| WHO recommendation on preeclampsia and eclampsia [ | International consensus | |
| WHO section for Hypertensive Disorders of Pregnancy from the WHO guideline on Pregnancy, childbirth, postpartum and newborn care [ | International consensus | |
| Hypertension section in the WHO guideline for managing complication in pregnancy [ | International consensus |
Identified scopes for improvement for Indonesian HDP management following comparison with international guidelines
| All pregnant women should have an initial assessment of risk factors of HDP and or preeclampsia, such as previous preeclampsia, chronic hypertension, any related comorbidities, and age during pregnancy. | |
| The women’s blood pressure should be checked at each antenatal visit. | |
| Low dose aspirin is prescribed for women with high risks of preeclampsia. | |
| Low dose aspirin is prescribed for women with high risks of preeclampsia from 12th week of pregnancy until the baby’s delivery. | |
| Calcium supplementation is prescribed for women with low calcium intake to prevent the event of preeclampsia. | |
| Women are asked about signs and symptoms of preeclampsia, such as headache, blurred visions, cramps, seizure, eclampsia feet, in each antenatal visit. | |
| Proteinuria/Dipstick test should be done at least once in each trimester. | |
| Once the Dipstick test are positive, the pregnant women are checked with any indicators of preeclampsia, such as: kidney function test, complete blood count, and liver function test. | |
| Once diagnose with preeclampsia, women are assigned for referral. | |
| Telephone communication with obstetricians prior to the referral to the hospital. | |
| Paramedic companion during the referral, completed with adequate emergency kits ambulance. | |
| Antihypertensive agents for the treatment of severe hypertensive disorder of pregnancy, such as calcium channel blockers, or methyldopa-should be available in the practice settings. | |
| Antihypertensive agents were considered once the women’s blood pressure reached SBP > 150 and or DBP > 100. | |
| Antihypertensive agents were prescribed without any delays once the women’s blood pressure reached SBP > 160 and or DBP > 110. | |
| Obstetricians led delivery is booked once women are diagnosed with the hypertensive disorders in pregnancy. | |
| Monitoring of sign and symptoms of preeclampsia, includes laboratories examination should be available in practice settings. | |
| Magnesium sulphate IV/IM should be available for the emergency treatment of eclampsia. | |
| The full regimens of magnesium sulphate IV/IM as treatment for eclampsia seizures. | |
| Women should be checked for any signs and symptoms of hypertensive disorder of pregnancy (HDP) and or preeclampsia at maximum of six week postpartum in primary care clinics. | |
| Almost of antihypertensive agents are safe during breastfeeding periods. | |
| Postpartum counselling about the risks of cardiovascular diseases for women with previous history of HDP. | |
| Women with history of HDP are offered with non-hormonal contraception. | |
| Periodic blood measure monitoring and cardiovascular assessment for women with history of HDP | |
| Counseling about lifestyle modification is offered for women with history of HDP | |
| Consideration of low dose of aspirin prescription for the next pregnancy. |
Guiding questions for FGD and interviews in pilot phase
| Project theoretical framework | Group of participants involved in the pilot phase | Guiding questions for the participants |
|---|---|---|
| Intervention | Primary care providers | What do you think about the pathways content? |
| Recipients’ (individuals involved in intervention implementation) characteristic | Obstetricians | What do you think about the pathways’ application in your clinics? |
| Policy makers & key informants | ||
| What are the supports needed for the pathway implementation? | ||
| Patients | ||
| What are the barriers and facilitators of the pathways’ implementation? | ||
| External Environment | ||
| What do you think if the pathways need a larger scale trial? | ||
| What do you think about the pathways’ implementation? | ||
|
| What do you think if the management is applied to other women? | |
| What are the barriers and facilitators of the management? | ||
| What do you think if the pathways need a larger scale trial? |